Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Free Cash Flow (2024 - 2025)

Evommune (EVMN) has disclosed Free Cash Flow for 2 consecutive years, with -$16.6 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 10.31% to -$16.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$35.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$76.5 million for FY2025, 31.21% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$16.6 million at Evommune, up from -$18.5 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$16.6 million in Q4 2025, with the low at -$18.5 million in Q4 2024.